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1. Introduction
  Mycosis granuloma is also known as mycosis fungoides 
(MF) which was named due to similarity of shape between 
skin nodules in this disease and mushroom instead of fungal 
infection, originally described by French dermatologist, 
Alibert, in 1806. MF is the most common type in primary 
cutaneous T-cell lymphoma (CTCL), accounting for 60% 
of new cases of CTCL, which generally progress slowly 
and could invade lymph nodes, bone marrow and visceral 
organs, eventually, develop to systemic lymphoma in 
later stage. The involvement of important visceral organs 
including lung, liver, kidney, pancreas, etc. occurred in 
20% of patients with severe skin lesions who would died 
due to secondary skin infection[1-3]. Patient age at a peak 
presentation raged from 55 to 60 years and female-male 
ratios was 1.6-2.3:1. 
2. Case report
  A 40-year-old woman was admitted because of 
generalized plaque and mass with pruritus for four years 
and getting worse for half a year on August 6th, 2009. The 
patient experienced pruritic plaque on her back in July 
2005 and was diagnosed as 'eczema' by local hospital. 
Symptoms were not improved after topical corticosteroid 
therapy. Enlarged cervical lymph nodes were presented and 
lymph node biopsy indicated reactive hyperplasia in 2006. 
Generalized plaques and mass got worse in January 2009 
and a head and facial biopsy showed mycosis fungoides 
(Figure 1), immunohistochemistry showed CD4 (++), CD68 
scattered (+). Bacterial culture of head exudate indicated: 
Staphylococcus aureus. She obtained improvement 
after receiving antimicrobial agents and symptomatic 
treatment. The patient experienced acute pancreatitis due 
to compression and invasion of a mass in the pancreatic 
head on July 9th, 2009 and obtained improvement after 
receiving antimicrobial and enzymes inhibitor therapy in 
Nanjing First Hospital. The results of PPD, blood culture, 
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sputum culture and hydrothorax culture were negative in 
hospital and no tumor cell was detected in hydrothorax. The 
bone marrow cytology test in our hospital on July 30th, 2009 
indicated granulocyte series hyperplasia, erythrocyte series 
slight hyperplasia and megacaryocyte series hyperplasia 
with clusters of platelet. Physical examination revealed 
generalized red or dark-red plaque and mass in various 
size of range from pigeon egg to goose egg on face and head, 
trunk and limbs, with partial fusion, rupture and exudate. 
Enlarged retroauricular and axillary lymph nodes were 
palpable and the large one was 3 cm×4 cm in size. Pitting 
edema of right lower extremity existed without tenderness. 
  This patient received intensively local care after 
hospitalization immediately. Washing out local exudates 
by topical saline every day, anti-infection with mupirocin 
ointment used in the area of ulcerate, intravenous 
infusion of vancomycin and other active anti infection, 
as well as supportive care were used to treat this patient. 
On August 12th, 2009, modified CHOP chemotherapy 
(cyclophosphamide 0.6 d1,8 + vincristine 2 mg d1,8 + 
epirubicin 30 mg d1,8 + prednisone 15 mg po. bid d1-14) 
plus polyethyleneglycol interferon毩-2a (Pegasys 180 毺g
qw) was administrated to this patient. After one week 
treatment, tumor on head and face regressed apparently, and 
exudate from ulceration was also obviously reduced. On Aug 
26th, this patient got a fever of 39.2 ℃, WBC: 0.3×109/L,
and was regarded as grade Ⅳ myelosuppression. Then, 
we used G-CSF, GM-CSF and infused 10 毺 leukocyte 
suspension to increase white blood cells. Meanwhile, the 
patient received active anti infection treatment, intensive 
care, ultraviolet disinfection in the ward regularly, as well 
as rigorous observation. After treated with these prompt 
supportive cares, the patient was improved. After two 
cycles of chemotherapy, the reexamination of PET/CT 
showed apparent tumor regression, pleural and pericardial 
effusion disappeared and the patient was evaluated with 
partial remission on September 30th, 2009. In cycle 3 
and 4, the patient occurred grade Ⅳ leucopenia and 
thrombocytopenia with fever and received G-CSF plus GM-
CSF to increase white blood cells, IL-11 to increase platelet, 
immunoglobulin for supportive care and platelet as well as 
leukocyte suspension. After treated with these supportive 
cares, the disease improved. On December 31st, 2009, the 
patient experienced dizziness and plantar numbness without 
vomiting. Brain MR showed flake abnormal signal shadow 
near left cerebellar and trigone of bilateral ventricle, local 
brain edema, regarded as intracerebral lymphoma invasion. 
The patient was infused with MTX 15 mg, dexamethasone 
3 mg through lumbar puncture on December 31st, 2009 
and January 7th, 2010, respectively, without any toxicities. 
The examination of cerebrospinal fluid routine test and 
biochemistry was normal, no tumor cells were detected 
by exfoliative cytological examination. The patient began 
the 5th cycle of chemotherapy on January 20th, 2010 with 
semustine 0.2 d1 + teniposide 50 mg d2-4 + dexamethasone 
10 mg d2-4. On February 25th, 2010, while compared 
with the result of PET/CT examination on September 30th, 
2010, reexamination of PET/CT showed FDG metabolism of 
right upper neck residual lymph node decreased, the FDG 
metabolism of other residual lymph nodes and residual 
plaque shadow in the right front upper pericardium did 
not increase, thickening subcutaneous tissue of head and 
neck was relieved. All these results indicated this treatment 
was effective. The result of cerebrospinal fluid routine test 
was normal. Because of effective treatment outcome, the 
patient received 6th cycle of consolidation chemotherapy 
on February 25th with MeCCNU 0.2 g d0 + VM-26: 50 mg 
d1-5 + DEX: 20 mg d1-5. The patients had finished six 
cycles of chemotherapy until April 30th 2010. Tumor 
was shrinking over 90%, pleural and pericardial effusion 
disappeared(Figure 2-4). Until last follow up date of January 
24th, 2011, the patient was still alive.
Figure 1. HE section, tumor cells invaded the superficial dermis(伊
200).
 
Figure 2. Change of skin lesions on head. 
A: before chemotherapy; B: One week after the first chemotherapy; C: 
After 5 cycles of chemotherapy.
 
Figure 3. 18F-FDG PET indicated that the FDG uptake of the tumor 
was decreased remarkably and the patient obtained partial remissions 
after 2 cycles of chemotherapy.
A: Before chemotherapy (Aug.7th, 2009); B: After chemotherapy (Sep. 
30th, 2009).
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Figure 4. Change of head lesions on PET/CT. FDG metabolism of 
skin lesions on head decreased, the tumor was shrinking over 90%.
A: Before chemotherapy (Aug.7th, 2009); B: After chemotherapy (Sep. 
30th, 2009).
3. Discussion
  MF is the most common form of cutaneous T-cell 
lymphoma, accounting for 60% of new cases, with 
an increase in incidence[4]. The cause of this disease 
is unclear to date, possibly related to heredity, viral 
infection, environment, occupational factor, drugs and 
etc. Histopathology: (1) Non-specific period: absence 
of specific changes and main features characterized as 
telangiectasia in dermal papilla layer, epithelial cell 
swelling and perivascular inflammatory cell infiltration. (2) 
Infiltration stage: infiltrate cells located in the epidermis 
mainly including heteromorphic reticular cells (mycosis 
cells), neutrophils, eosinophils, lymphocytes and tissue 
cells and etc. and presence of oval-shaped, gyral-shaped or 
irregular mycosis cells that are slightly larger than normal 
lymphocytes and had hyper chromatic, irregularly contoured 
nuclei as well as karyomitosis, and round microabscess 
in the epidermis which had diagnostic significance. (3) 
Tumor stage: tumor cells proliferation into groups invading 
dermis layer and even subcutaneous tissue and muscle. 
Clinical manifestations: The course of MF could last for a 
long time and skin lesions were variably present, which 
could be similar to various skin diseases, therefore, the 
diagnosis of MF was usually confirmed many years after 
the initial appearance of skin symptoms. This disease is 
generally divided into 3 stages: patch stage, plaque stage 
and tumor stage. In patch stage, skin lesion is atypical 
and non-specific, which is similar to dermatitis, eczema, 
psoriasis and etc. In plaque stage, skin lesion evolves 
into irregular invasive plaque, and clinically differential 
diagnosis includes actinic reticulosis, cutaneous pseudo-T-
cell lymphoma, large-plaque parapsoriasis, lymphomatoid 
papulosis, alopecia mucinosa, Ki-1 positive anaplastic lagre 
cell lymphoma, peripheral T-cell lymphoma, and etc[5,6]. In 
tumor stage, tumors present as hemispherical, fungating or 
irregular shape, soft and reddish-brown mass. Patient will 
feel intolerable pain if rupture occurs. Ulcerative lesions 
usually cause infection and secondary sepsis which are the 
most common cause of death resulted from MF. Diagnosis: 
it is not difficult to confirm diagnosis according to history, 
clinical features and biopsy. Heteromorphic reticular cell 
and microabscess in the epidermis are the main evidences 
of histopathological diagnosis. Treatment: Recently, no 
curative therapy for MF existed. The objective of treatment is 
to induce remission, reduce tumor burden as far as possible, 
meanwhile, and protect immune function of patients. Early 
treatment for this disease could obtain better outcome 
and therapeutic approaches include: 1) Electron beam 
irradiation: electron irradiation of local or systemic skin 
is one of the basic treatment methods; 2) Immunotherapy: 
the response rate of interferon treatment can approach 
50%, with common dose of 3-6 Mu, thrice every week, by 
intramuscular or subcutaneous injection; 3) Local drug 
treatment: traditional treatment including tropical corticoid, 
chemotherapeutic drugs (nitrogen mustard, carmustine, 
etc). 4) Light therapy: UVB (ultraviolet irradiation) or 
PUVA (psoralen+UVA)[7], extracorporeal photopheresis. 
5) Systemic chemotherapy: restricted to recurrent, local 
chemotherapy failure or lymph node and visceral invasion 
patient. Lower dose of methotrexate and single gecitabine[8], 
polyethyleneglycol adriamycin are effective. Response rate 
of combination chemotherapy was 81%, median response 
duration range from 5 to 41 months, and commonly used 
regimens included CVP, CHOP, CAVE and etc. CHOP could 
provide high response rate.
  This patient initially presented skin symptoms in 2005, and 
was definitely diagnosed with mycosis fungoides by biopsy 
and immunohistochemistry in June, 2009. It was difficult 
to clinically establish a diagnosis of MF due to absence of 
specific symptoms. When general drugs were ineffective 
for refractory rash accompanying with intractable pruritus, 
examinations of histopathology and immunohistochemistry 
should be performed as early as possible. Biopsy should 
be repeated, if necessary, to confirm diagnosis when prior 
biopsy did not obtained definite result[9]. This patient 
was in tumor stage when she was admitted to hospital, 
with generalized skin, lymph nodes and visceral organs 
involvement. There were many unfavourable factors during 
treatment period as follow: This patient had a history of 
acute pancreatitis within a month prior to admission, which 
was possibly related to tumor suppression and invasion, 
however, acute pancreatitis could occurred again at any 
time during treatment period; Generalized rupture and 
exudation were present on systemic skin, causing infection 
and recurrent high fever during hospitalization; this patient 
experienced sever hypoproteinemia, with albumin of 21.1 g/L,
bilateral moderate pleural effusion and pericardial effusion; 
Grade 4 myelosuppression, febrile neutropenia, secondary 
infection and septic shock frequently occurred during 
chemotherapy. For the rare, severe case, we collected and 
consulted relevant professional knowledge and clinical 
case report. Firstly, we strengthened local care, closely 
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cooperated with department of hematology and dermatology, 
and then established CHOP-based chemotherapy and 
systemic treatment; During treatment period, we actively 
communicated with the patient, closely observed disease 
progression and timely adjusted treatment regimen; After 
treatment, discharge guidance and close follow-up were 
performed. Significant head tumor shrinking was observed 
after one week treatment through reasonable arrangement 
and treatment.  The patient obtained partial remissions 
after 2 cycles of chemotherapy. Most tumors regressed after 
6 cycles of chemotherapy, with good quality of life and 
progression-free survival of 7 months. Overall survival of 
the patient was more than 17 months until last follow-up 
date of January 24th, 2011. For this patient with advanced 
and severe MF, CHOP in combination with interferon 毩-2a 
effectively controlled disease, improved quality of life and 
prolonged survival time. 
  Recently, with the development of biological techniques, 
new styles of target drugs bring new hope to MF treatment. 
These new drugs include bexarotene, denileukin, diftitox, 
vorinostat, zanolimumab and alemtuzumab. Bexarotene is 
a novel retinoid that is specifically selective for retinoid X 
receptors to regulate cellular proliferation, differentiation 
and apoptosis. The oral and external (1%) formulation of 
Bexarotene were approved by the FDA in 1999 and 2000, 
respectively, for conventional method failure patients with 
early stage of cutaneous T cell lymphoma. Denileukin 
diftitox is an engineered protein combining interleukin-2 
and diphtheria toxin which can bind to high affinity 
interleukin-2 receptors(CD25) expressed in some leukemias 
and lymphomas malignant cells. In a Phase III clinical study, 
this drug was administrated to patients after other treatment 
failure and obtained overall response rate of 30% as well 
as median response duration of 6.9 months[10]. Vorinostat 
is a histone deacetylase inhibitor. Histone deacetylase 
inhibitor is an intensive inducer of histone deacetylation, 
cell cycle arrest and apoptosis. In a IIB study, Seventy four 
patients with persistent, progressive or refractory CTCL 
were treated with vorinostat, with overall response rate 
and median time to progression of 29.7% and 4.9 months, 
respectively. This drug is the first HDAC inhibitor approved 
for CTCL indication. Zanolimumab, an anti-CD4 antibody, 
and alemtuzumab, an anti-CD52 antibody, have shown 
promising efficacy for advanced MF[11]. Otherwise, other new 
drugs including pentostatin, temozolomide and bortezomib 
also have certain therapeutic effect[12,13]. 
  For refractory or advanced disease, high-dose 
chemotherapy in combination with autologous stem cell 
transplantation (SCT) is used to treat patient with CTCL. 
However, this treatment provide limited clinical benefits, 
with short-term remissions and high relapse rate, therefore, 
it is used but with decreasing frequency. There were only 
case report and small study on allogeneic SCT treatment 
for advanced MF. Data from the study about allogeneic SCT 
indicated that graft-versus-T cell lymphoma effect existed, 
with long-term remissions in highly selected patients. 
Currently, except allogeneic SCT, there is no definite 
treatment that could provide long-term remissions or cure 
for patients with advanced MF. Moreover, clinical trial 
of new drug was also alternative treatment option for all 
patients with recurrent or advanced disease. 
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